These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21762988

  • 1. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA, Poon H.
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [Abstract] [Full Text] [Related]

  • 2. Tadalafil for the treatment of pulmonary arterial hypertension.
    Klinger JR.
    Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653
    [Abstract] [Full Text] [Related]

  • 3. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ, PHIRST Study Group.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):768-74. PubMed ID: 22818063
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
    Bharani A, Patel A, Saraf J, Jain A, Mehrotra S, Lunia B.
    Indian Heart J; 2007 Aug 21; 59(4):323-8. PubMed ID: 19126937
    [Abstract] [Full Text] [Related]

  • 10. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
    Kiliçkesmez K, Küçükoğlu MS.
    Anadolu Kardiyol Derg; 2010 Sep 21; 10 Suppl 2():16-8. PubMed ID: 20819751
    [Abstract] [Full Text] [Related]

  • 11. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP, Durst L, Burger CD, Oudiz RJ, Bourge RC, Franco V, Waxman AB, McDevitt S, Walker S.
    J Cardiovasc Pharmacol Ther; 2014 Nov 21; 19(6):550-7. PubMed ID: 24742768
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
    Levin YD, White RJ.
    Drugs Today (Barc); 2011 Feb 21; 47(2):145-56. PubMed ID: 21431102
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
    Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N, Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group.
    Am J Respir Crit Care Med; 2011 Jun 15; 183(12):1723-9. PubMed ID: 21471085
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.